Tatva Chintan Pharma Chem Announces ₹1 Dividend, Reports ₹1.08 Billion Revenue and ₹10.3 Million Profit in March Quarter

Tatva Chintan Pharma Chem Ltd has declared its financial performance for the quarter ended March 2025, with a consolidated revenue from operations of ₹1.08 billion. The manufacturer of specialty chemicals reported a consolidated net profit of ₹10.3 million during the March quarter, indicating the continued challenges in the industry and a competitive operating environment.

 

In spite of the lean profit, the board of the company has declared a final dividend of ₹1 on each equity share of ₹10 face value, pending the approval of the shareholders. The decision reflects Tatva Chintan's focus on rewarding its shareholders, even as the company goes through a phase of low growth and margin pressure.

 

Tatva Chintan, with its broad portfolio of specialty chemicals, remains committed to operational excellence and cost controls to drive profitability. The company's financials reflect a conservative but consistent approach, with an almost debt-free balance sheet and continued efforts at optimizing its product mix and market coverage.

 

Management is upbeat about long-term outlook, citing investment in innovation and premium segment focus as future drivers of growth. The dividend declaration is viewed as a good sign of stability and shareholder value in an uncertain market environment.

 

Source: Reuters